News
-
CDMO Recipharm said that it is now offering services for reformulation of MDIs with new lower global warming potential propellants such as HFA 152a and HFO 1234ze. The company also announced that it has partnered… Read more . . .
-
According to Opiant Pharmaceuticals, a pharmacodynamic study of the company’s OPNT003 intranasal nalmefene met its primary endpoint of non-inferiority compared to intranasal naloxone, with 3 mg of OPNT003 almost twice as effective as 4 mg… Read more . . .
-
Evoke Pharma announced that the FDA has granted new drug product exclusivity for Gimoti metoclopramide nasal spray, giving the company exclusive marketing rights for 3 following the initial approval date. The FDA approved Gimoti for… Read more . . .
-
According to Neurelis, the US Patent and Trademark Office (USPTO) has issued a new patent covering Valtoco diazepam nasal spray. The abstract for US Patent No. 11,241,414, titled “Administration of benzodiazepine compositions,” says that it… Read more . . .
-
Inhaler monitoring company Adherium has announced the appointment of Francis White as VP of Global Business Development. White was most recently Managing Director of Olympus Medical in the UK and Ireland and previously held business… Read more . . .
-
According to Iliad Biotechnologies, the company has received a 3-year, $1 million grant from the National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health (NIH) for pre-clinical development of its B-Tech intranasal… Read more . . .
-
Virpax Pharmaceuticals said that nasal delivery of its VRP324 dry powder cannabidiol in a rodent model produced high concentrations of CBD in the brain. In September 2021, Virpax announced that it had licensed Nanomerics’s molecular envelope… Read more . . .
-
Australian pharmaceutical company Firebrick Pharma has announced the initiation of a Phase 2 trial of its Nasodine povidone-iodine nasal spray for the reduction of viral shedding in patients with COVID-19. According to Firebrick, a 2001 pilot… Read more . . .
-
The FDA has granted Breakthrough Therapy designation to Zambon’s CMS I-neb colistimethate sodium for the treatment of non-cystic fibrosis bronchiectasis (NCFB) in adult patients with chronic P. aeruginosa lung infections, the company said. The FDA… Read more . . .
-
Inhalation API manufacturer Inke has announced a €9 million expansion of its manufacturing facility in Castellbisbal, Barcelona, Spain “to reinforce focus on inhalation micronized APIs,” with the aim of tripling its production capacity by 2024.… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden